Move targets branded and patented drugs; Indian pharma sector braces for impact

US President Donald Trump has announced a sweeping 100 per cent tariff on all branded and patented pharmaceutical imports, effective October 1, 2025—a move that could hit India’s drug industry hard.

“Starting October 1st, 2025, we will be imposing a 100 per cent Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump said in a Truth Social post, clarifying that “IS BUILDING” would mean “breaking ground” or being “under construction.” Products linked to such projects would be exempt.

View this post on Instagram

A post shared by IDU (@defencealerts)

The decision underscores Trump’s tariff-heavy economic strategy, which

See Full Page